Results 151 to 160 of about 27,891 (313)

Update on Non‐Biological and RNA‐Based Therapeutics in Chronic Inflammatory Diseases: Precision Medicine Through Small Molecules: An EAACI Position Paper

Allergy, EarlyView.
ABSTRACT In the last decades, critical advancements in research technology and knowledge on disease mechanisms steered therapeutic approaches for chronic inflammatory diseases towards unprecedented target specificity. For allergic and chronic lung diseases, biologic drugs pioneered this goal, acquiring on the way—through the clinical use of monoclonal ...
F. Roth‐Walter, I. M. Adcock, C. Benito‐Villalvilla, R. Bianchini, L. Bjermer, G. Caramori, L. Cari, K. F. Chung, Z. Diamant, I. Eguiluz‐Gracia, E. F. Knol, M. Jesenak, F. Levi‐Schaffer, G. Nocentini, L. O'Mahony, O. Palomares, F. Redegeld, M. Sokolowska, B. Van Esch, M. Zurlo, C. Stellato   +20 more
wiley   +1 more source

Peri‐operative management of diabetes mellitus: a multidisciplinary consensus statement from the Association of Anaesthetists and the Joint British Diabetes Societies for Inpatient Care group

Anaesthesia, EarlyView.
Summary Introduction Surgery in patients with diabetes mellitus is associated with increased morbidity and mortality compared with those who do not have diabetes mellitus. This is likely multifactorial and could be attributed to organisational issues; dysglycaemia; hospital‐acquired diabetic ketoacidosis; errors with insulin prescribing and ...
Nicholas A. Levy, Kariem El‐Boghdadly, Dileep N. Lobo, Daniel J. Stubbs, Parizad Avari, Donal Buggy, Claire Frank, Kim Howson, Jinty Moffett, Emma Morris, Omar G. Mustafa, Glynn Nash, Pádraig Ó Scanaill, Sarah Procter, Gerry Rayman, Kim Russon, Caroline Thomas, Sarah Tinsley, Allan Xu, Ketan Dhatariya   +19 more
wiley   +1 more source

Sexual Safety Signals of Common Antidiabetic Drugs: Insights From FAERS Disproportionality Analysis

Andrology, EarlyView.
ABSTRACT Background Erectile dysfunction is a prevalent and distressing complication of diabetes mellitus that markedly affects quality of life in male patients. Although the role of diabetes in erectile dysfunction is well‐established, potential drug‐induced sexual dysfunction associated with commonly prescribed antidiabetic medications remains ...
Shan Lin, Xuefeng Ding, Xin Dang, Qingyuan Zhan   +3 more
wiley   +1 more source

A Qualitative Analysis of Patient Experiences Using Semaglutide 2.4 mg for Weight Loss

Obesity Science & Practice
Introduction Semaglutide 2.4 mg (Wegovy) is the first second‐generation anti‐obesity medication approved by the FDA for long‐term obesity treatment. Given the effectiveness of semaglutide 2.4 mg compared to first‐generation anti‐obesity medications and ...
Eion Plenn, Dylan Amin, Jonathan Henry, Gabrielle Leavitt, Jason Walker, Taraneh Soleymani   +5 more
doaj   +1 more source

Timing and duration of glucagon‐like peptide‐1 receptor agonist use and risk of nonarteritic anterior ischaemic optic neuropathy

Acta Ophthalmologica, EarlyView.
Abstract Purpose To investigate the association between glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) use and nonarteritic anterior ischaemic optic neuropathy (NAION) in type 2 diabetes, examining treatment recency and cumulative duration. Methods This nationwide registry‐based nested case–control study utilizedz Danish health registries (1996 ...
Siar Niazi, Filip Gnesin, Baker Nawfal Jawad, Zia Niazi, Puriya Daniel Wuertz Yazdanfard, Anne P. Toft‐Petersen, Kathrine Kold Sørensen, Amani Meaidi, Yousif Subhi, Christian Torp‐Pedersen   +9 more
wiley   +1 more source

Az antidiabetikumok kardiovaszkuláris szerepe a véletlen besorolásos vizsgálatokban és az újabb ajánlások világában = Cardiovascular role of novel antidiabetics in randomized controlled trials and newer recommendations [PDF]

, 2017
Bajnok, László
core   +1 more source

Semaglutide vs Liraglutide for Weight Loss in Adults with Obesity [PDF]

Introduction: Obesity is a growing chronic condition worldwide with limited effective and safe treatment options. Semaglutide and liraglutide are two GLP-1a medications with encouraging outcomes for the treatment of obesity.
Bar, Orian
core   +1 more source

Dynamics of Body Composition and Metabolic Risk in Adolescents With Obesity Under GLP‐1 Receptor Agonist Therapy

Acta Paediatrica, EarlyView.
ABSTRACT Aim To explore changes in body composition in adolescents with obesity treated with glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) and their association with metabolic syndrome (MetS) components. Methods This real‐world retrospective study included adolescents (12–18 years) with obesity who received multidisciplinary lifestyle‐based ...
Adar Lopez, Liat Perl, Eyal Cohen‐Sela, Ophir Borger, Yael Issan, Hagar Interator, Erez Azoulay, Hadar Moran‐Lev, Ronit Lubetzky, Shira Zelber‐Sagi, Yael Lebenthal, Avivit Brener   +11 more
wiley   +1 more source

Is there a role for cannabidiol in obesity, metabolic syndrome and binge eating?

British Journal of Pharmacology, EarlyView.
Cannabidiol (CBD) is one of the most abundant phytocannabinoids isolated from the Cannabis sativa plant. CBD is a lipophilic, non‐intoxicating substance that differently from Δ9‐tetrahydrocannabinol (Δ9‐THC) does not present the typical profile of a drug of abuse.
Luca Botticelli, Emanuela Micioni Di Bonaventura, Giacomo Einaudi, Gustavo Provensi, Alessia Costa, Claudio D'Addario, Carlo Cifani, Maria Vittoria Micioni Di Bonaventura   +7 more
wiley   +1 more source

Glucagon‐like peptide‐1 receptor agonists and muscle strength changes in older adults: Risks beyond muscle mass reductions

British Journal of Pharmacology, EarlyView.
Abstract Gastric inhibitory polypeptide (GIP)/Glucagon‐like peptide‐1 (GLP‐1) receptor agonists are increasingly prescribed for the management of obesity and type 2 diabetes, yet research pertinent to their effects on muscle health is limited. Considering the central role of muscle strength as a sarcopenia component, this article summarizes emerging ...
Konstantinos Prokopidis
wiley   +1 more source